Prion Propagation Mechanism: Cell-to-Cell Transmission and Neurotoxicity
Overview
flowchart TD
experiments_prion_propagation_["prion-propagation-mechanism"]
experiments_prion_propagation_["Cell-to-Cell"]
experiments_prion_propagation_ -->|"related to"| experiments_prion_propagation_
style experiments_prion_propagation_ fill:#81c784,stroke:#333,color:#000
experiments_prion_propagation_["Transmission"]
experiments_prion_propagation_ -->|"related to"| experiments_prion_propagation_
style experiments_prion_propagation_ fill:#81c784,stroke:#333,color:#000
experiments_prion_propagation_["Neurotoxicity"]
experiments_prion_propagation_ -->|"related to"| experiments_prion_propagation_
style experiments_prion_propagation_ fill:#81c784,stroke:#333,color:#000
experiments_prion_propagation_["experiment"]
experiments_prion_propagation_ -->|"related to"| experiments_prion_propagation_
style experiments_prion_propagation_ fill:#81c784,stroke:#333,color:#000
style experiments_prion_propagation_ fill:#4fc3f7,stroke:#333,color:#000
...Prion Propagation Mechanism: Cell-to-Cell Transmission and Neurotoxicity
Overview
Mermaid diagram (expand to render)
This experiment investigates the mechanisms by which [prions](/entities/prnp) propagate between cells in the [brain](/brain-regions/), focusing on neuron-to-neuron, neuron-to-glia, and glia-to-neuron transmission. Understanding these propagation mechanisms is essential for developing therapies that can block [prion](/entities/prnp) spread and preserve neural circuitry. This connects to the broader [prion-like propagation](/mechanisms/extracellular-vesicle-tnt-mediated-spreading-comparison) literature in [neurodegenerative diseases](/diseases/).
Scientific Rationale
Prion diseases are characterized by the templated conversion of the cellular prion protein ([PrP^C](/entities/prnp)) to the disease-associated isoform ([PrP^Sc](/entities/prnp)). While the fundamental mechanism of conversion is well-characterized, the cellular pathways governing [prion](/entities/prnp) propagation and spread remain incompletely understood. This templated conversion mechanism is shared across [neurodegenerative proteinopathies](/diseases/), including [alpha-synuclein](/entities/alpha-synuclein) in [Parkinson's disease](/diseases/parkinsons-disease), [tau](/entities/tau-protein) in [Alzheimer's disease](/diseases/alzheimers-disease), and [TDP-43](/proteins/tardbp) in [ALS](/diseases/amyotrophic-lateral-sclerosis) and [FTD](/diseases/frontotemporal-dementia). Specifically:
Transmission mechanisms: How do prions move between cells—[exosomes](/mechanisms/extracellular-vesicles), [tunneling nanotubes](/mechanisms/extracellular-vesicle-tnt-mediated-spreading-comparison), direct cell contact, or [synaptic activity](/mechanisms/synaptic-dysfunction-pathway)?
Neuronal vulnerability: Why are certain neuronal populations preferentially lost?
Glial involvement: What role do [astrocytes](/cell-types/astrocytes) and [microglia](/cell-types/microglia) play in prion propagation and clearance?
Therapeutic targets: Can we block cell-to-cell spread without preventing normal [PrP^C](/entities/prnp) function?Answering these questions will reveal novel therapeutic targets for prion disease treatment.
Hypothesis
Prion propagation occurs via multiple complementary mechanisms (synaptic transmission, exosome release, and direct cell contact), with astrocytes serving as critical amplifiers of prion load. Blocking specific propagation pathways will reduce neurotoxicity and slow disease progression.
Experimental Design
Model Systems
In vitro:
- Neuronal cultures (iPSC-derived neurons)
- Astrocyte-neuron co-cultures
- [Microglia](/cell-types/microglia)neuron co-cultures
- 3D brain organoids
2.
In vivo:
- Prion-infected mice with cell-type specific reporters
- Conditional PrP^Sc expression models
Experimental Approach
Aim 1: Define Propagation Pathways (Months 1-12)
In vitro studies:
- Develop fluorescently tagged prion reporters
- Test transmission in:
- Neuron-neuron monocultures
- Neuron-astrocyte co-cultures
- Neuron-microglia co-cultures
- Test pharmacological inhibitors:
- Exosome release (GW4869)
- Synaptic transmission (tetrodotoxin)
- Tunneling nanotube formation (cytochalasin D)
- Protease-based clearance
In vivo validation:
- Use Cre-lox system to trace prion spread from specific cell populations
- Perform optogenetic mapping of affected circuits
Aim 2: Identify Neurotoxic Species (Months 9-18)Biochemical characterization:
- Separate PrP^Sc species by size (oligomers vs. fibrils)
- Test toxicity of each fraction in neuronal cultures
- Correlate species with clinical severity in patient samples
Cellular readouts:
- Calcium imaging to assess functional impairment
- Mitochondrial function assays
- Apoptosis markers (caspase activation, TUNEL)
- Transcriptomic profiling of infected vs. uninfected neurons
Aim 3: Therapeutic Target Validation (Months 15-24)Screen for propagation blockers:
- FDA-approved drug library (1,500 compounds)
- siRNA/shRNA library targeting synaptic proteins
- CRISPR knockout of candidate genes
In vivo validation:
- Test top candidates in prion-infected mice
- Assess survival, clinical score, PrP^Sc burden
- Evaluate neuronal preservation via MRI and histology
Expected Outcomes
Propagation mechanism map: Complete characterization of cell-to-cell transmission pathways
Toxic species identification: Correlation of specific PrP^Sc conformers with neurotoxicity
Therapeutic targets: 3-5 validated molecular targets for blocking prion propagation
Lead compounds: 2-3 existing drugs suitable for repurposingKey Metrics
| Metric | Target |
|--------|-------|
| Propagation pathways characterized | ≥4 distinct mechanisms |
| Toxic PrP^Sc species identified | ≥2 distinct conformers |
| Drug candidates identified | ≥10 with >50% reduction in spread |
| In vivo validation candidates | ≥3 |
Feasibility Assessment
- Technical feasibility: HIGH — established in vitro prion models and imaging techniques
- Model availability: MEDIUM — requires development of new reporter systems
- Timeline: 24 months
Cost Estimate
| Component | Cost (USD) |
|-----------|------------|
| Cell culture and differentiation | $180,000 |
| Prion propagation studies | $150,000 |
| Drug screening | $250,000 |
| Animal model studies | $300,000 |
| Bioinformatics | $120,000 |
| Personnel (3 FTE × 2 years) | $450,000 |
| Total | $1,450,000 |
Risk Mitigation
- Risk: Prion infection efficiency in vitro variability → Mitigation: Use multiple cell lines and standardized protocols
- Risk: Drug screening hits not translating to in vivo → Mitigation: Include pharmacokinetics in early screening
- Risk: Off-target effects of propagation blockers → Mitigation: Validate in human neurons, test functional outcomes
Cross-Disease Connections: Prion-Like Propagation in Neurodegeneration
The [prion-like propagation](/mechanisms/extracellular-vesicle-tnt-mediated-spreading-comparison) mechanisms identified in this experiment are directly relevant to other [neurodegenerative diseases](/diseases/):
Propagation Pathways Across Diseases
| Disease | Protein | Key Propagation Mechanisms |
|---------|---------|---------------------------|
| [Parkinson's disease](/diseases/parkinsons-disease) | [α-synuclein](/entities/alpha-synuclein) | [Exosomes](/mechanisms/extracellular-vesicles), [tunneling nanotubes](/mechanisms/extracellular-vesicle-tnt-mediated-spreading-comparison), trans-synaptic spread |
| [Alzheimer's disease](/diseases/alzheimers-disease) | [Tau](/entities/tau-protein), [Aβ](/entities/amyloid-beta) | [Synaptic spread](/mechanisms/synaptic-dysfunction-pathway), [exosome](/mechanisms/extracellular-vesicles)-mediated |
| [ALS/FTD](/diseases/amyotrophic-lateral-sclerosis) | [TDP-43](/proteins/tardbp), [FUS](/proteins/fused-in-sarcoma) | [Stress granules](/mechanisms/stress-granules), [RNA granule](/mechanisms/stress-granules) transfer |
| [Huntington's disease](/diseases/huntingtons-disease) | [mHTT](/genes/htt) | [Exosome](/mechanisms/extracellular-vesicles)-mediated, trans-synaptic |
Therapeutic Targets for Propagation Blockade
- Exosome inhibition: [GW4869](/therapeutics/exosome-inhibition-neurodegeneration) blocks [prion](/entities/prnp) and [α-synuclein](/entities/alpha-synuclein) release
- Tunneling nanotube disruption: [Cytochalasin D](/therapeutics/cytochalasin-d-neuroprotection) blocks intercellular transfer
- Synaptic transmission blockade: [Tetrodotoxin](/therapeutics/synaptic-transmission-blockade) (TTX) — too broad for clinical use; selective targets needed
- Antibody therapy: [Anti-PrP](/therapeutics/anti-prion-antibodies) and [anti-α-synuclein antibodies](/therapeutics/alpha-synuclein-antibodies) can neutralize extracellular conformers
References
[Prusiner, Prions (1998)](https://pubmed.ncbi.nlm.nih.gov9822349/)
[Caughey & Lansbury, Protofibrils, pores, fibrils, and neurodegeneration (2003)](https://pubmed.ncbi.nlm.nih/12700375/)
[Kanu et al., Cell-to-cell spread of prions (2002)](https://pubmed.ncbi.nlm.nih.com11850651/)
[Liu et al., Astrocytes in prion disease (2019)](https://pubmed.ncbi.nlm.nih/30655581/)
[Herrmann et al., Prion propagation in vitro (2015)](https://pubmed.ncbi.nlm.nih/26391795/)
[Aguzzi & Calella, Prions: protein aggregation and infectious diseases (2009)](https://pubmed.ncbi.nlm.nih/19722608/)See Also
- [Neurodegeneration](/wiki/diseases-neurodegeneration) — implicated_in
Pathway Diagram
The following diagram shows the key molecular relationships involving prion-propagation-mechanism discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)